Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 179

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 179
---
ally disclaimed over an earlier filed patent. In the United States, the patent term of a patent that covers an
FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent
term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond
the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review.
Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval,
only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using
it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend
the term of a patent that covers an approved drug. In the future, if and when our product candidates receive FDA approval, we expect
to apply for patent term extensions on patents covering those product candidates. We plan to seek patent term extensions to any issued
patents we may obtain in any jurisdiction where such patent term extensions are available.

In some instances, we submit
patent applications directly to the USPTO as provisional patent applications. Corresponding non-provisional patent applications must
be filed not later than 12 months after the provisional application filing date. While we intend to timely file non-provisional
patent applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result
in the issuance of patents that provide us with any competitive advantage.

We will file U.S. non-provisional
applications and Patent Cooperation Treaty (“PCT”) applications that claim the benefit of the priority date of earlier filed
provisional applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority
date of the provisional patent application, and to designate all of the PCT member states in which national phase patent applications
can later be pursued based on the international patent application filed under the PCT. The PCT search authority performs a patentability
search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications
in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant
to seek protection in any of the member states through national